MET and prostate cancer: Collectively, these data indicated that the oleocanthal-based HVS is a robust inhibitor of the HGF/c-Met signaling axis and its important downstream pathways mediating proliferation, survival, and motility in different cancer models, with superior activity over S-oleocanthal, especially in prostate cancer model, consistent with the scattering and spheroid growth assay results.